^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thyroid Gland Carcinoma
    Drug:AIC100 (ICAM-1-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PRNewswire
    Title:

    AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

    Published date:
    05/17/2021
    Excerpt:
    AffyImmune Therapeutics...announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.